Actual state of affairs and future perspectives of SPECT radiopharmaceuticals regarding local and international data were summarized. Beyond conventional gamma-emitting radioisotopes, localization studies with beta emitting therapeutic radiopharmaceuticals hold increasing importance. Extension of hybrid (SPECT/CT) equipments has modified conventional scintigraphic and SPECT methods as well but more important changes come into the world through novel ligands for specific diagnoses and therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Background: Dopamine transporter (I-FP-CIT) single-photon emission tomography (SPECT) and I-meta-iodobenzylguanidine (I-MIBG) image play roles as indicative biomarkers in diagnosing patients with dementia with Lewy bodies (DLB). Brain- and body-first subtypes of DLB were hypothesized implying that subset of DLB may have normal I-FP-CIT or I-MIBG results, respectively. The purpose of this study was to explore the diagnostic sensitivity of two combination imaging modalities (I-FP-CIT SPECT and I-MIBG image) in patients with DLB and examine the clinical difference between brain- and body-first subtype.
View Article and Find Full Text PDFBackground: Autopsy studies in Lewy Body Disease (LBD) indicate that cardiac sympathetic denervation precedes Lewy body pathology and neuronal loss in the brain. Myocardial 123I-metaiodobenzylguanidine (MIBG) scintigraphy noninvasively assesses postganglionic cardiac sympathetic denervation in LBD and is considered an important biomarker in the international diagnostic criteria of Dementia with Lewy Bodies and Parkinson's Disease (PD). Despite the internationally recognized importance of MIBG scintigraphy in LBD, its use in neurodegenerative disorders is not FDA approved for this indication and is rarely used in the US for neurological research.
View Article and Find Full Text PDFDevelopment of Tc-Labeled Complexes with a Niraparib HYNIC Derivative for PARP-Positive Tumor Imaging.
Mol Pharm
January 2025
Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.
As an enzyme that plays an important role in DNA repair, poly(ADP-ribose) polymerase-1 (PARP-1) has become a popular target for cancer therapy. Nuclear medicine molecular imaging technology, supplemented by radiolabeled PARP-1 inhibitors, can accurately determine the expression level of PARP-1 at lesion sites to help patients choose an appropriate treatment plan. In this work, niraparib was modified with a hydrazinonicotinamide (HYNIC) group to generate the ligand NPBHYNIC, which has an affinity (IC) of 450.
View Article and Find Full Text PDF[This corrects the article DOI: 10.3389/fchem.2023.
View Article and Find Full Text PDFRetrospective study of post-treatment I SPECT/CT imaging for personalizing therapy of patients with differentiated thyroid cancer.
Folia Med (Plovdiv)
December 2024
Military Medical Academy, Sofia, Bulgaria.
The absence of anatomical landmarks in the whole body scan makes it challenging to precisely localize 131I uptake, which is used to treat patients with differentiated thyroid cancer (DTC). Recently, SPECT/CT studies have been utilized to increase the diagnostic sensitivity and specificity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!